Introduction
============

Colorectal cancer (CRC) is the second commonest malignancy in males and females in Europe [@B1] and the third in the United States [@B2]. Huge resources are being invested in prevention and early diagnosis of this disease. Population-based screening campaigns try to discover as much early tumors and precursor lesions as possible, aiming to decrease the incidence of the disease, to simplify the clinical management of patients once the lesion develops, and to improve survival [@B3]. However, despite of the advances in screening, surgery and radio and chemotherapy, it is still the second cause of cancer deaths in the developed countries [@B4].

The molecular classification of CRC proposed by Jass in 2007 [@B5] has been of much help in the understanding of the diverse etiopathogenetic mechanisms of this disease. From a pathological perspective, adenomatous lesions in the large bowel are fully accepted precursors of CRC and the adenoma-carcinoma sequence still provides a solid model for research on carcinogenesis [@B4],[@B6]. These adenomatous polyps and subsequent carcinoma appear to develop with sequential genetic alterations which affect to the expression of several proteins, such as peptidases [@B7],[@B8].

Peptidases play a key role in cell proliferation, angiogenesis and tumor invasiveness by regulating extracellular matrix degradation and cell signalling and recognition [@B8],[@B9]. The expression and activity of these enzymes vary in cancer depending on the several clinicopathological parameters like histological grade, stage, and patient survival [@B8]-[@B11]. For this reason, peptidases are useful tools in the development of clinical strategies for treatment and follow up of cancer patients.

Although the role of these proteins in carcinogenic processes and their potential usefulness as tumor markers in CRC was initially proposed for cell-surface enzymes [@B8],[@B12],[@B13], it has been demonstrated that cytosolic peptidases also participate in several hallmarks of cancer [@B14]-[@B19]. In addition, it has been reported that the activity of different cytosolic peptidases such as puromycin-sensitive aminopeptidase (PSA or EC 3.4.11.14), aminopeptidase B (APB or EC 3.4.11.6) and pyroglutamyl-peptidase I (PGI or EC 3.4.19.3) was altered in breast [@B19],[@B20], kidney [@B21],[@B22] and thyroid tumors [@B23].

Regarding CRC, recently we demonstrated that the activity and mRNA expression of prolyl endopeptidase (PEP) and aspartyl aminopeptidase (ASP), was altered throughout the uninvolved colorectal mucosa-adenoma-carcinoma sequence. Moreover, tissue and plasmatic activity of both enzymes was correlated with tumor invasiveness and 5-year survival of CRC patients [@B16]-[@B18]. All these evidences point to the analysis of cytosolic peptidases as a promising tool in the design of new diagnostic/prognostic biomarkers in CRC.

In this context, the objective of the present work was to study the activity and mRNA expression of PSA, APB and PGI in the adenoma-adenocarcinoma sequence and plasma samples from patients with CRC, and to correlate the obtained results with classic histopathological parameters for tumor prognosis and survival.

Materials & Methods
===================

The authors declare that all the experiments carried out in this study comply with current Spanish laws and conform to the principles outlined in the Declaration of Helsinki.

Patients
--------

81 patients with CRC were prospectively included in the study. Males predominated in the series (51M/30F), the average age being 70.1 years for males and 67 years for females. Mean follow-up was 50.2 months (range 3-80). All patients received partial colectomies. In 16 of these patients, both adenomatous polyps and adenocarcinomas were diagnosed. These cases were used to analyze peptidase activity and mRNA levels throughout the uninvolved mucosa-adenoma-adenocarcinoma sequence.

Follow-up was closed by December 31, 2012. At that time, 25 patients had died of disease. AJCC system [@B24] has been applied to assign Stage and Grade. Clinical data included in the study were retrieved from the patient clinical records and are summarized in Table [1A](#T1A){ref-type="table"}. Plasma was also collected preoperatively and analyzed in 40 of these patients. Table [1B](#T1B){ref-type="table"} shows the clinicopathological data in this subset of patients. Plasma from 28 healthy volunteers with no clinical history of neoplastic diseases was used as control sample.

Tissue Specimens
----------------

Surgical resections were submitted *in fresh* to the Pathology Lab within a period of 30 minutes after removal. Handling of specimens was performed following conventional protocols for the management of surgical resections of colon and rectum [@B25]. Tumor characteristics were recognized on gross examination and selected fragments of tumor were frozen in isopentane and stored at -80ºC. Besides, peripheral venous blood samples from 40 of these patients were collected prior to surgery in EDTA tubes and centrifuged at 1500 rpm during 15 minutes. The obtained plasma was also stored at -80ºC. Enzyme assays have also been performed in plasma obtained from 28 healthy volunteers (matched by sex and age).

Sample preparation
------------------

Explanted tumor and non-tumor samples were homogenized in 10 mM Tris-HCl buffer at pH 7.4, using a Heidolph PZR 50 Selecta homogenizer, and ultracentrifuged in a Centrikon T-2070 Kontron Instruments apparatus at 100,000*g* for 35 minutes. The resulting supernatants (soluble fractions) were used to measure PGI, APB and PSA activity [@B19],[@B26]. Previously collected plasma samples were used to determine plasmatic PGI, APB and PSA activity. All the above-described steps were carried out at 4 °C.

PGI, APB, PSA activity measurements
-----------------------------------

PGI, APB and PSA activity was fluorimetrically measured using a modified version of the method described by Zambotti-Villela et al. [@B27]. PGI was quantified with pGlu-β-naphthylamide (0.125mM) as substrate and APB with Arg-β-naphthylamide (0.125mM). In the case of PSA was measured using Ala-β-naphthylamide (0.125mM) as substrate. To discriminate between PSA and aminopeptidase N forms of total alanine aminopeptidase activity, incubations with the specific PSA inhibitor puromycin (40µM) were performed in parallel.

The assay is based on the fluorescence of β-naphthylamine generated from the hydrolysis of the substrate by the enzyme. The components of the assays mixtures (1 ml) included the following: PGI assay \[(50mM of sodium phosphate buffer (pH 7.4), 2 mM of DL-dithiothreitol and 0.1mg/ml of bovine serum albumin)\]; APB assay \[(50mM of sodium phosphate buffer (pH 7.4),150 mM NaCl, puromycin (40µM) and 0.1mg/ml of bovine serum albumin, pH 6.5)\]; PSA assay \[(50mM of sodium phosphate buffer (pH 7.4), puromycin (40µM) and 0.1mg/ml of bovine serum albumin\].

The reaction was initiated by adding 30μL (APB and PSA) or 50μL (PGI) of tissue or plasma sample to 1mL of the assay mixture. This was incubated at 37ºC for 30 minutes and the reaction was stopped by addition of 1 mL of 0.1M sodium acetate buffer (pH 4.2). The excitation and emission wavelengths were 345 and 412 nm, respectively. Blanks were used to determine background fluorescence. Relative fluorescence was converted into picomoles of product using a standard curve constructed with increasing concentrations of β-naphthylamine.

Protein concentration was measured in triplicate by the Bradford method [@B28], using BSA (1 mg/mL) as calibrator. Results from the CRC tissues and from plasma samples were recorded as units of peptidase per milligram of protein (UP/mg prot) and per liter of plasma (UP/L), respectively. One unit of peptidase activity (UP) is the amount of enzyme required to release one pmol of β-naphthylamine per minute. Fluorogenic assays were linear with respect to hydrolysis time and protein content.

Real-time quantitative PCR analysis
-----------------------------------

Quantitative RT-PCR for detecting *PGPEP1* (PGI), *RNPEP* (APB) and *NPEPPS* (PSA) mRNA was performed to determine the transcription levels of these peptidases. The RNA of tumor and nontumor tissue samples from CRC patients was isolated with the RNeasy Protect kit (Qiagen), including a DNase digestion step using an RNase-free DNase kit (Qiagen) to exclude possible contamination by genomic DNA. First-strand cDNA was synthesized from 25 µg of total RNA from each human sample using Moloney murine leukemia virus reverse transcriptase and random hexamers according to the manufacturer\'s instructions (first-strand cDNA Synthesis Kit, Amersham Biosciences, Essex, UK). The resulting cDNA samples were amplified by PCR (7900 Real-Time PCR System, Applied Biosystems) with specific oligonucleotide primer pairs designed with the analysis software Primer 3 and synthesized by Sigma-Genosys (Cambridge, UK).

Based on previous experiments on CRC [@B17], human renal cell carcinoma [@B21] and other human tissues [@B29], TATA box binding protein (TBP), peptidylprolyl isomerase A (PPIA), Hypoxantine phosphoribosyltransferase 1 (HPRT1), Polymerase(RNA)II(DNA directed) polypeptide A (POLR2 A), Glyceraldehyde-3´´-phosphate dehydrogenase (GAPDH) and succinate dehydrogenase complex subunit A (SDHA) were chosen as endogenous reference genes. The sequences of the primers used to amplify PGI, APB, PSA and the six housekeeping genes are shown in Table [2](#T2){ref-type="table"}. All primers were synthesized and purified by Sigma-Genosys (Cambridge, UK).

Statistical analysis
--------------------

Kolmogorov-Smirnov and Shapiro-Wilk tests were applied to data obtained from tissue and plasma samples respectively to know if the numbers followed or not a normal distribution. Based on this information (p\<0.05), peptidase activities in tissue and plasma were analyzed with non parametric probes: Mann-Whitney test and Kruskal-Wallis tests were used to detect differences between two or three groups, respectively. Spearman\`s correlation test was performed to evaluate the correlation between tissue and plasmatic activities and with tumor size and patients\' gender.

Finally, Kaplan-Meier curves and log-rank test were performed to evaluate the association between soluble peptidase activities and 5-year survival. The compared groups were created by cut-off points based on median enzyme activity values, as previously reported [@B30],[@B31]. A Cox regression model was used to test the independent effects of clinical and pathological variables and peptidase activity on five-year overall survival. SPSS® 21.0 software was used for the statistical analysis.

Results
=======

Peptidase activity and mRNA expression in tissue specimens
----------------------------------------------------------

APB and PSA peptidase activity was significantly higher in tumor samples (adenoma and adenocarcinoma) than in the adjacent non-tumor tissue (Kruskal-Wallis, p=0.001 for APB and p=0.0001 for PSA). In the adenomas the activity was near to three and two-fold higher than the uninvolved mucosa, respectively. PGI activity was higher in adenocarcinomas, however it did not reach statistical significance (Kruskal-Wallis, p= 0.2). Results are summarized in Table [3A](#T3A){ref-type="table"}.

These differences were not correlated with mRNA levels. Thus, *PGPEP1* (PGI) and *NPEPPS* (PSA) were downregulated in tumor specimens compared with non-neoplasic tissue (Kruskal-Wallis, p\<0.001 for both genes) and *RNPEP* (APB) mRNA levels were similar throughout the uninvolved mucosa-adenoma-adenocarcinoma sequence (Table [3B](#T3B){ref-type="table"}).

Peptidase activity in CRC tissue according to clinicopathological variables and topographic distribution
--------------------------------------------------------------------------------------------------------

Adenocarcinomas with low grades showed higher PGI activity than high grade tumors (Mann-Whitney, p=0.011). A similar tendency was observed in CRCs showing lymphatic invasion, although this result was not significant (Mann-Whitney, p=0.05). PSA and APB activities did not revealed significant changes. These results are summarized in Table [1A](#T1A){ref-type="table"}.

Topographic distribution of adenocarcinomas displayed significant differences in all the analyzed peptidases, with higher activities in adenocarcinomas located in the colon than in the rectum (Mann-Whitney, p\<0.05 for all cases) (Table [1A](#T1A){ref-type="table"}). To elucidate if these significant differences between the two topographies, colon and rectum, were related with the chemo-radiotherapy regimes previously administered to some patients with rectal adenocarcinoma, we compared enzyme activities in cases with and without this previous treatment. However, it did not throw any significant result (Mann-Whitney, p \> 0.05 in all cases).

We also analyzed if there is any correlation between tissue and plasmatic activities, and between tumor size and patients\' gender and enzyme activities. We only found a statistically significant correlation between tissue PGI activity and tumor size (Spearman Rho test, r= -0.248, p= 0.04) (Figure [1](#F1){ref-type="fig"}).

Peptidase activity in tissue according to overall survival
----------------------------------------------------------

Kaplan-Meier curves and log-rank test showed that five-year overall survival (OS) of patients with CRC was better when PGI activity was higher than 165 UP/mg of protein (log-rank p=0.002) (Figure [2](#F2){ref-type="fig"}A). A similar trend was observed with APB and PSA (cut-off value 15000 UP/mg for both enzyme activities), when five-year OS was analyzed by log-rank test, although it did not reach statistical significance (p=0.07 and p=0.057, respectively).

Multivariate Cox regression model showed that PGI activity (p=0.04) and grouped stage (p=0.04) were independent factors influencing patient OS (Fig [2](#F2){ref-type="fig"}B).

Peptidase activity in plasma samples compared with controls and according to overall survival and other clinicopathological variables
-------------------------------------------------------------------------------------------------------------------------------------

Plasma from CRC patients and healthy individuals showed similar peptidase activities (Mann-Whitney test p\>0.05) (Table [4](#T4){ref-type="table"}). The stratification of data according to clinicopathological variables also showed no significant changes (Table [1B](#T1B){ref-type="table"}).

The analysis of APB activity in plasma samples displayed similar results to those obtained in tumor tissue. Thus, when plasmatic APB activity was higher than 90 UP/L the OS was significantly better in Kaplan-Meier curves (Fig [3](#F3){ref-type="fig"}A) (log-rank p=0.042). Multivariate analysis showed that APB activity (p=0.03) and local invasion (p=0.02) are independent prognostic factors of OS (Fig [3](#F3){ref-type="fig"}B).

Discussion
==========

Many studies have revealed that the altered expression and activity of several peptidases may play a role in tumor transformation and progression of CRC. Thus, some authors have proposed that the analysis of these enzymes may have a predictive value in the early detection and prognosis of patients with CRC [@B10],[@B16],[@B17],[@B31]-[@B32]. In this sense, the first studies pointed to cell-surface peptidases such as dipeptidyl-peptidase IV (DPPIV/CD26) [@B10], aminopeptidase N (APN/CD13) [@B31] and fibroblast activation protein (FAP) [@B32] as a new tumor markers and promising targets for CRC therapy. However, we recently reported that cytosolic peptidases may be also of interest in the searching of new markers and targets for this disease [@B16],[@B17]. So, to throw more light to this question, in this study we analyzed the activity and mRNA expression of three cytosolic enzymes (APB, PSA and PGI) in colorectal tissues and plasma from a series of CRC patients (see the flow-chart in the Figure [4](#F4){ref-type="fig"}).

The adenoma-adenocarcinoma sequence in the large bowel describes that the gradual progression from normal to dysplastic epithelium, and hence to carcinoma, is associated with the accumulation of genetic imbalances [@B5],[@B6]. It has long been reported that expression of several proteases, such as matrix metalloproteinases (MMPs) and peptidases, increases gradually throughout the sequence, playing an important role in the development and progression of these tumors [@B33],[@B34]. Furthermore, some studies have suggested that the coordinated action of MMPs and aminopeptidases is important for the progression of several neoplastic diseases [@B8],[@B35]. In a previous work, we observed that PEP activity increased significantly in the preneoplastic adenomatous lesions, then stabilizing in adenocarcinomas [@B18]. In the present study, 16 adenoma-adenocarcinoma sequences from the same patients were analyzed. Spectrofluorimetric assay showed that PSA and APB activity was increased significantly in colorectal tumors, but particularly in the adenomas, where it was two and three-fold higher (respectively) than in the adjacent uninvolved mucosa.

On the other hand, the analysis of CRC tissues also showed that the activity of PGI correlated negatively with the histological grade and tumor size. Moreover, 5-year overall survival of CRC patients was significantly better when tissue PGI activity was higher. In our previous analysis with ASP and PEP, higher tissue activities also correlated with less aggressive forms and with better patient survival [@B16],[@B17]. All this findings taken together suggest that the tissue activity of these cytosolic enzymes may be a marker of early forms and prognosis of CRC.

Quantitative RT-PCR assays showed that the mRNA levels were not correlated with the enzyme activity in colorectal tissues. Thus, (PSA) and (PGI) levels were higher in the not cancerous mucosa than in CRC and the adenomatous tissues, and mRNA levels of *RNPEP* (APB) did not change significantly throughout the adenoma-carcinoma pathway. This discrepancy between mRNA and the protein expression/activity has been described in several studies, which could be due to alterations in mRNA translation efficiency, posttranslational modifications like phosphorylation or acethylation, and mRNA and protein synthesis and degradation rates [@B8],[@B22],[@B36]-[@B38]. Besides, this lack of correlation is widely spread in renal diseases involving altered energy metabolism like diabetes-induced renal hypertrophy, diabetes-induced matrix synthesis or angiotensin II induced renal injury, and hence, it could be a strong possibility for cancer cells to show this discrepancy [@B38]-[@B41]. These phenomena illustrate the importance of not relying only on mRNA level the evaluation of any protein change [@B38].

Topographic distribution of adenocarcinomas also displayed significant differences in all the analyzed peptidases. Thus, rectal carcinomas showed decreased enzyme activities compared with colonic adenocarcinomas. Recently, we demonstrated a similar distribution of PEP activity in CRC tissues and observed that it was decreased significantly in rectal cancer tissues from patients who received chemo-radiotherapy preoperatively for a better control of the disease [@B17]. Similar patterns were observed with other proteases, which indicate that these enzymes could be of potential use in clinical practice to predict the response to preoperative chemo-radiotherapy [@B42],[@B43]. We did not observe any change in the activity of PSA, APB and PGI in rectal cancer in response to preoperative treatment and, therefore, further studies are necessary to know the cause of these topographic differences.

Previous studies in a wide variety of tumors have demonstrated that cytosolic peptidases may change their activities depending on the tumor type or on the phase of development where the tumor is. For example, it has been reported increased APB, PSA and PGI activities in breast [@B19],[@B20] and thyroid tumors [@B23] with respect to uninvolved tissues. PSA and PGI activities were also increased in high grade clear cell renal cell carcinomas [@B22] and higher APB activity was correlated with better prognosis of these patients [@B11]. However, these enzymes did not change their activity in head and neck cancers [@B41]. So, these data support the idea that tumor growth regulation by peptidases occur in a tumor specific manner [@B8].

Cytosolic and cell-surface peptidases can be released to diverse body fluids, including plasma, urine, pleural and peritoneal effusions. Although the origin of these circulating enzymes is still controversial, the comparative studies of peptidase profiles among cancer patients and control subjects have yielded significant results in several studies [@B10],[@B17],[@B20],[@B30],[@B45]-[@B47]. Furthermore, the correlation among plasma/serum values and classic histopathological parameters for tumor aggressiveness and survival have pointed to these enzymes as useful biomarkers for helping in screening, diagnosis, staging, prognosis and monitoring cancer therapy [@B10],[@B17]-[@B20],[@B30],[@B45]-[@B47].

In this work we did not found any significant difference in the analyzed peptidases in plasma between CRC patients and healthy individuals. However, higher plasmatic APB activity was independently associated with longer patient survival. Although this result was opposite of that described previously with ASP and PEP, which plasmatic activities correlated positively with poorer survival rate [@B16],[@B17], these evidences also point to the determination of cytosolic peptidases in plasma as a valuable method in the determination of CRC prognosis. Further studies focusing on the molecular translation of this descriptive analysis with higher number of patients would be advisable to confirm the prognostic significance of these data.

Conclusion
==========

The present study shows for the first time that the activity and mRNA levels of PSA, APB and PGI are altered throughout the colorectal adenoma-carcinoma sequence and that the activity of tissue PGI and plasmatic APB are independent prognostic factors for the 5-year survival of CRC patients. Taken into account that CRC is a major health problem in developed countries, the arrival of cell-surface but also cytosolic peptidases as new diagnostic tools with prognostic impact may be particularly profitable in hospital practice.
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![**Representation of the correlation between PGI activity and tumor size in CRC.**Values represent mean ± SE of enzyme activity recorded as units of enzyme per milligram of protein (UP/mg prot). Spearman\'s rho test: coefficient (r) = -0.248; p\< 0.05.](ijmsv12p0458g001){#F1}

![**Kaplan-Meier curves and Multivariate Analysis (Cox regression model) with PGI activity in CRC tissues.**Overall survival (2A) of 81 CRC patients according to their tumor PGI activity pattern. Multivariate (2B) analysis of clinicopathological variables and tumor PGI activity in predicting overall survival of patients with CRC.](ijmsv12p0458g002){#F2}

![**Kaplan-Meier curves and Multivariate Analysis (Cox regression model) with APB activity in plasma from CRC patients.** Overall survival (3A) of 40 CRC patients according to their plasmatic APB activity pattern. Multivariate (3B) analysis of clinicopathological variables and tumor APB plasmatic activity in predicting overall survival of patients with CRC.](ijmsv12p0458g003){#F3}

![Flow-chart summarizing the most important findings of this study.](ijmsv12p0458g004){#F4}

###### 

**Peptidase activity in CRC tissue according to clinicopathological characteristics.** Values are means ± SE of peptidase activity recorded as pmol of units of peptidase (UP) per milligram of protein.

  Variables                      n =   APB            PSA            PGI                                           
  ------------------------------ ----- -------------- -------------- ---------------- ----------- ---------------- -----------
  **Grade**                                                                                                        
  Low (G1-G2)                    64    13946 ± 1104   0.101          15570 ± 1164     0.385       186.84 ± 28.12   **0.011**
  High (G3-G4)                   17    12591 ± 4562   13058 ± 2994   126.25 ± 5.89                                 
  **Stage**                                                                                                        
  Low (T1-T2)                    11    11474 ± 2471   0.847          13894 ± 2418     0.916       152.2 ±55.52     0.606
  High (T3-T4)                   70    14235 ± 1229   15501 ± 1214   183.96 ± 27.64                                
  **Nodal invasion**                                                                                               
  No                             50    13429 ± 1371   0.625          14510 ± 1316     0.839       164.6 ± 18.09    0.820
  Yes                            31    14493 ± 1920   16810 ± 1865   209.33 ± 69.79                                
  **Distant Metastases**                                                                                           
  No                             74    13757 ± 1177   0.589          14797 ± 1105     0.349       185.31 ± 26.72   0.183
  Yes                            7     13776 ± 3797   18917 ± 4143   119.33 ± 44.22                                
  **Lymphatic invasion**                                                                                           
  No                             72    13606 ± 1179   0.333          15118 ± 1144     0.548       188.44 ± 27.74   0.050
  Yes                            9     14714 ± 3517   15884 ± 3580   116.25 ± 25.7                                 
  **Vascular invasion**                                                                                            
  No                             66    14479 ± 1166   0.161          15379 ± 1082     0.705       192.04 ± 29.9    0.429
  Yes                            15    11000 ± 2838   14629 ± 3401   126.5 ± 22.11                                 
  **Perineural invasion**                                                                                          
  No                             77    13677 ± 1139   0.861          15120 ± 1111     0.846       180.21 ± 25.33   0.949
  Yes                            4     12948 ± 2542   15584 ± 2019   154 ± 24.4                                    
  **Grouped stage**                                                                                                
  Low (0-IIC)                    46    13505 ± 1443   1.000          14332 ± 1375     0.542       162.84 ± 18.98   0.758
  High (IIIA-IV)                 35    14242 ± 1735   16918 ± 1671   208.2 ± 62.44                                 
  **Topographic distribution**                                                                                     
  Colon                                14064 ± 828    **0.023**      16108 ± 724      **0.044**   195 ± 18         **0.026**
  Rectum                               10580 ± 1162   13009 ± 1142   130 ± 15                                      

###### 

**Peptidase activity in plasma from CRC patients according to clinicopathological characteristics.** Values are means ± SE of units of peptidase per liter of plasma (UP/L).

  Variables                 n =   APB              PSA              PGI                                     
  ------------------------- ----- ---------------- ---------------- ---------------- ------- -------------- -------
  **Grade**                                                                                                 
  Low (G1-G2)               33    100.16 ± 7.63    0.364            395.80 ± 38.71   0.064   25.24 ± 4.23   0.242
  High (G3-G4)              7     88.75 ± 19.23    253.25 ± 43.82   8.49 ± 0.91                             
  **Stage**                                                                                                 
  Low (T1-T2)               9     100.6 ± 24.84    0.915            360 ± 113        1.000   9.27 ± 1.37    0.421
  High (T3-T4)              31    98.17 ± 7.05     379.5 ± 36.5     25.77 ± 4.38                            
  **Nodal invasion**                                                                                        
  No                        29    98.9 ± 7.16      0.802            380.35 ± 45.65   0.918   29.74 ± 4.79   0.073
  Yes                       11    97.89 ± 16.8     366.78 ± 52.56   7.78 ± 0.65                             
  **Distant Metastases**                                                                                    
  No                        37    97.23 ± 6.6      0.959            378.81 ± 38.22   0.700   23.57 ± 4.09   0.330
  Yes                       3     110.33 ± 42.99   353 ± 82.6       17.39 ± 11.14                           
  **Lymphatic invasion**                                                                                    
  No                        34    95.8 ± 6.7       0.519            373 ± 39.42      1.000   25.39 ± 4.21   0.068
  Yes                       6     116 ± 30.92      395.75 ± 69.66   7.56 ± 1.31                             
  **Vascular invasion**                                                                                     
  No                        33    101.96 ± 7.94    0.669            396.56 ± 41.03   0.557   23.49 ± 4.51   0.522
  Yes                       7     85.67 ± 14.91    297.83 ± 56.03   20.77 ± 6.83                            
  **Perineural invasion**                                                                                   
  No                        38    98.93 ± 7.25     0.862            380.32 ± 35.97   0.829   22.26 ± 3.88   0.328
  Yes                       2     89 ± 6.1         259 ± 31.2       41.74 ± 8.23                            
  **Grouped stage**                                                                                         
  Low (0-IIC)               28    99.84 ± 7.48     0.740            388.47 ± 47.36   0.885   29.23 ± 5.02   0.136
  High (IIIA-IV)            12    96.2 ± 15.12     352.7 ± 49.07    10.96 ± 3.23                            

###### 

**Sequence of forward (F) and reverse primers (R) of indicated target genes and the size expected for each PCR-amplified product.** Primers for the assayed housekeeping genes are also shown.

  Enzyme/HKG                                        Gene Symbol   Forward Primer                  Reverse Primer                  Amplicon size (bp)
  ------------------------------------------------- ------------- ------------------------------- ------------------------------- --------------------
  *Piroglutamyl aminopeptidase*                     *PGPEP1*      5´-GCCCTGTGGGAGAAGCAC-3´        5´-AGCCCCTTGTAGCCCTTGTT-3´      110
  *Aminopeptidase B*                                *RNPEP*       5´-CGAAGCATCTTAGCCGATGAC-3´     5´-TCGATCAAACTCAAAACCTGGA-3´    102
  *Aminopeptidase puromycin sensitive*              *NPEPPS*      5´-CGTTAGAAGAAGCCCGTCGT-3´      5´-AAAGTAGTGCCATCACCATGCTT-3´   118
  *TATA box binding protein*                        *TBP*         5´-GGATAAGAGAGCCACGAACCAC-3´    5´-TTAGCTGGAAAACCCAACTTCTG-3´   139
  *Succinate dehydrogenase complex, subunit A*      *SDHA*        5´-TCTGCCCACACCAGCACT-3´        5´-CCTCTCCACGACATCCTTCC-3´      142
  *Peptidylpropyl isomerase A*                      *PPiA*        5´-GGTCCCAAAGACAGCAGAAAA-3´     5´-TCACCACCCTGACACATAAACC-3´    114
  *Hypoxantine phosphoribosyltransferase 1*         *HPRT1*       5´-GCCAGACTTTGTTGGATTTGA-3´     5´-GGCTTTGTATTTTGCTTTTCC-3´     130
  *Polymerase(RNA)II(DNA directed) polypeptide A*   *POLR2A*      5´-ACATCACTCGCCTCTTCTACTCC-3´   5´-GTCTTGTCTCGGGCATCGT-3´       268
  *Glyceraldehyde-3´´-phosphate dehydrogenase*      *GAPDH*       5´-CAATGCCTCCTGCACCAC-3´        5´-CCTGCTTCACCACCTTCTTG-3´      350

###### 

**Peptidase activity in tissue from CRC patients.**Values are means + SE of peptidase activity recorded as pmol of units of peptidase (UP) per milligram of protein. **a:** Adenocarcinoma *vs* Adenoma; **b:** Adenocarcinoma *vs* Normal; **c:** Adenoma *vs* Normal.

  Peptidase        UP/L (Mean ± S.E)   Mann- Whitney (p =)
  ---------------- ------------------- ---------------------
  **APB**                              
  Adenocarcinoma   13298 ± 693         0.073^a^
  Adenoma          27812 ± 4202        0.002^b^
  Non-tumoral      10952 ± 1531        0.001^c^
  **PSA**                              
  Adenocarcinoma   15355 ± 621         0.443^a^
  Adenoma          19747 ± 2296        0.0001^b^
  Non-tumoral      10587 ± 880         0.001^c^
  **PGI**                              
  Adenocarcinoma   176 ± 14.35         0.145^a^
  Adenoma          138 ± 12.02         0.156^b^
  Non-tumoral      151 ± 18.38         0.934^c^

###### 

**Peptidase mRNA expression.**Values are means ± SE of peptidase mRNA expression recorded as relative units. **a:** Adenocarcinoma *vs* Adenoma; **b:** Adenocarcinoma *vs* Normal; **c:** Adenoma *vs* Normal.

  Peptidase            Relative Units (Mean ± S.E )   Mann-Whitney (p =)
  -------------------- ------------------------------ --------------------
  ***RNPEP* (APB)**                                   
  Adenocarcinoma       163.93 ± 34.81                 0.144^a^
  Adenoma              174.8 ± 15.76                  0.797^b^
  Non-tumoral          153.76 ± 26.03                 0.312^c^
  ***NPEPPS* (PSA)**                                  
  Adenocarcinoma       107.89 ± 15.36                 0.001^a^
  Adenoma              36.06 ± 6.2                    0.029^b^
  Non-tumoral          166.29 ± 20.2                  0.0001^c^
  ***PGPEP1* (PGI)**                                  
  Adenocarcinoma       43.15 ± 7.17                   0.005^a^
  Adenoma              13.73 ± 2.12                   0.001^b^
  Non-tumoral          157.07 ± 41.39                 0.0001^c^

###### 

**Peptidase activity in plasma from CRC patients.**Values are means ± SE of units of peptidase per liter of plasma (UP/L).

  Peptidase   UP/L (Mean ± S.E )   Mann-Whitney (p =)
  ----------- -------------------- --------------------
  **APB**                          
  Patient     95.37 ± 5.34         0.106
  Control     105.29 ± 6.57        
  **PSA**                          
  Patient     338.07 ± 30.14       0.873
  Control     340.71 ± 48.47       
  **PGI**                          
  Patient     21.63 ± 3.11         0.988
  Control     18.61 ± 3.29         
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